EP1163327A1 - Human protein kinase b gamma polypeptides and a method for disrupting protein kinase b gamma in a non-human - Google Patents
Human protein kinase b gamma polypeptides and a method for disrupting protein kinase b gamma in a non-humanInfo
- Publication number
- EP1163327A1 EP1163327A1 EP00921244A EP00921244A EP1163327A1 EP 1163327 A1 EP1163327 A1 EP 1163327A1 EP 00921244 A EP00921244 A EP 00921244A EP 00921244 A EP00921244 A EP 00921244A EP 1163327 A1 EP1163327 A1 EP 1163327A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- protein kinase
- nucleic acid
- human
- human protein
- acid molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102000005765 Proto-Oncogene Proteins c-akt Human genes 0.000 title claims abstract description 28
- 238000000034 method Methods 0.000 title claims abstract description 21
- 101000798007 Homo sapiens RAC-gamma serine/threonine-protein kinase Proteins 0.000 title claims description 31
- 108010045717 Proto-Oncogene Proteins c-akt Proteins 0.000 title claims description 24
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 43
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 41
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 41
- 239000013598 vector Substances 0.000 claims abstract description 21
- 229920001184 polypeptide Polymers 0.000 claims abstract description 18
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 18
- 150000001875 compounds Chemical class 0.000 claims abstract description 16
- 238000012360 testing method Methods 0.000 claims abstract description 12
- 230000026731 phosphorylation Effects 0.000 claims abstract description 9
- 238000006366 phosphorylation reaction Methods 0.000 claims abstract description 9
- 230000004155 insulin signaling pathway Effects 0.000 claims abstract description 8
- 238000012216 screening Methods 0.000 claims abstract description 6
- 210000004027 cell Anatomy 0.000 claims description 23
- 239000002773 nucleotide Substances 0.000 claims description 19
- 125000003729 nucleotide group Chemical group 0.000 claims description 19
- 150000001413 amino acids Chemical class 0.000 claims description 15
- 108020004414 DNA Proteins 0.000 claims description 11
- 241001465754 Metazoa Species 0.000 claims description 11
- 108091034117 Oligonucleotide Proteins 0.000 claims description 10
- 230000000694 effects Effects 0.000 claims description 10
- 239000000523 sample Substances 0.000 claims description 9
- 230000009261 transgenic effect Effects 0.000 claims description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 6
- 230000000692 anti-sense effect Effects 0.000 claims description 5
- 230000033228 biological regulation Effects 0.000 claims description 5
- 238000009396 hybridization Methods 0.000 claims description 5
- 230000001105 regulatory effect Effects 0.000 claims description 5
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 4
- 230000002068 genetic effect Effects 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 241000244203 Caenorhabditis elegans Species 0.000 claims description 3
- 102000053602 DNA Human genes 0.000 claims description 3
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 3
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 3
- 108020004999 messenger RNA Proteins 0.000 claims description 3
- 238000013519 translation Methods 0.000 claims description 3
- 108700028369 Alleles Proteins 0.000 claims description 2
- 108091026890 Coding region Proteins 0.000 claims description 2
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims description 2
- 230000000295 complement effect Effects 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000002853 nucleic acid probe Substances 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 108091008611 Protein Kinase B Proteins 0.000 abstract description 14
- 101000779418 Homo sapiens RAC-alpha serine/threonine-protein kinase Proteins 0.000 abstract description 4
- 210000004556 brain Anatomy 0.000 abstract description 3
- 230000003213 activating effect Effects 0.000 abstract 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 14
- 238000003752 polymerase chain reaction Methods 0.000 description 11
- 239000002299 complementary DNA Substances 0.000 description 10
- 102000004877 Insulin Human genes 0.000 description 7
- 108090001061 Insulin Proteins 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 229940125396 insulin Drugs 0.000 description 7
- 101710103995 RAC-gamma serine/threonine-protein kinase Proteins 0.000 description 6
- 102100032314 RAC-gamma serine/threonine-protein kinase Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 102000001253 Protein Kinase Human genes 0.000 description 4
- 239000011543 agarose gel Substances 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 108060006633 protein kinase Proteins 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 238000000636 Northern blotting Methods 0.000 description 3
- 238000012181 QIAquick gel extraction kit Methods 0.000 description 3
- 102100032315 RAC-beta serine/threonine-protein kinase Human genes 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 101000798015 Homo sapiens RAC-beta serine/threonine-protein kinase Proteins 0.000 description 2
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 101710113459 RAC-alpha serine/threonine-protein kinase Proteins 0.000 description 2
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 2
- 101710156940 RAC-beta serine/threonine-protein kinase Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 101100322915 Caenorhabditis elegans akt-1 gene Proteins 0.000 description 1
- 101100162366 Caenorhabditis elegans akt-2 gene Proteins 0.000 description 1
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 1
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108700001097 Insect Genes Proteins 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- 108700005443 Microbial Genes Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- -1 PKBα Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102100030264 Pleckstrin Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 101000797994 Rattus norvegicus RAC-alpha serine/threonine-protein kinase Proteins 0.000 description 1
- 101000798006 Rattus norvegicus RAC-beta serine/threonine-protein kinase Proteins 0.000 description 1
- 101000798012 Rattus norvegicus RAC-gamma serine/threonine-protein kinase Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 150000001576 beta-amino acids Chemical group 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 102000044506 human AKT2 Human genes 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000000021 kinase assay Methods 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 108010026735 platelet protein P47 Proteins 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
Definitions
- the present invention relates to human protein kinase B polypeptides and to nucleic acid molecules coding for such polypeptides.
- the invention further relates to vectors and cells comprising said nucleic acid molecules, as well as to methods for screening test compounds which affect the insulin signaling pathway.
- Insulin plays a key role in regulating a wide range of cellular processes.
- the activation of class la phopshoinositide 3-kinase (PI 3-kinase) is necessary to elicit many of insulin's effects on glucose and lipid metabolism (for reviews, see Shepherd, P.R. et al. (1998) Biochem. J. 333, 471-490; Alessi, D.R. & Downes, C.P. (1998) Biochim. Biophys. Acta 1436, 151-164).
- PI 3-kinase act in insulin signaling is by binding to pleckstrin homology (PH) domains of phosphoinositide-dependent protein kinase (PDK1) and protein kinase b (PKB).
- PH pleckstrin homology
- PDK1 phosphoinositide-dependent protein kinase
- PKTB protein kinase b
- Protein kinase B (for reviews, see e.g. Coffer, P.J. et al. (1998) Biochem. J. 335, 1-13: Alessi, D.R. & Cohen, P. (1998) Current Opinion in Genetics & Development 8, 55-62) has also been called Akt or RAC (Related to protein kinase A and C).
- Akt Protein kinase A and C.
- IGF1 insulin growth factor 1
- PKB ⁇ possess an N-terminal PH domain and a residue equivalent to Thr 308 (Thr 305 in PKB ⁇ ).
- Thr 308 Thr 305 in PKB ⁇ .
- PKB ⁇ has a C-terminal truncation of 23 residues and thereby lacks a residue equivalent to Ser 473 (see e.g. Coffer et al., supra; Alessi & Downes, supra; Alessi & Cohen, supra; Walker et al. (1998) Biochem. J. 331, 299-308). It has thus been believed that PKB ⁇ is activated solely via phosphorylation of Thr 305 .
- human protein kinase B ⁇ is a protein comprising 479 amino acids, including the 23 amino acid C-terminal region lacking in the enzyme cloned from rat brain (Konishi et al., supra). Human protein kinase B ⁇ comprises not only the phosphorylation residue Thr 305 but also a putative second phosphorylation residue Ser 472 .
- this invention provides an isolated nucleic acid molecule selected from:
- nucleic acid molecules comprising a nucleotide sequence as shown in SEQ ID NO: 1 and which codes for human protein kinase B ⁇ ;
- nucleic acid molecules comprising a nucleotide sequence capable of hybridizing under stringent hybridization conditions to a nucleotide sequence complementary the polypeptide coding region of a DNA molecule as defined in (a) and which codes for human protein kinase B ⁇ , or a functionally equivalent modified form thereof;
- nucleic acid molecules comprising a nucleic acid sequence which is degenerate as a result of the genetic code to a nucleotide sequence as defined in (a) or (b) and which codes for human protein kinase B ⁇ , or a functionally equivalent modified form thereof.
- stringent hybridization conditions is known in the art from standard protocols (e.g. Current Protocols in Molecular Biology, editors F. Ausubel et al., John Wiley and Sons, Inc. 1994, or Sambrook, J., Fritsch, E.F. and Maniatis, T., Molecular Cloning: A laboratory manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY 1989) and could be understood as e.g. hybridization to filter-bound DNA in 0.5 M NaHPO 4 , 7% sodium dodecyl sulfate (SDS), 1 mM EDTA at +65°C, and washing in O.lxSSC / 0.1% SDS at +68°C.
- SDS sodium dodecyl sulfate
- the said nucleic acid molecule has a nucleotide sequence identical with SEQ ID NO: 1 of the Sequence Listing.
- the nucleic acid molecule according to the invention is not to be limited strictly to the sequence shown as SEQ ID NO: 1. Rather the invention encompasses nucleic acid molecules carrying modifications like substitutions, small deletions, insertions or inversions, which nevertheless encode proteins having substantially the biochemical activity of protein kinase B ⁇ . Included in the invention are consequently nucleic acid molecules, the nucleotide sequence of which is at least 85% homologous, preferably at least 90 or 95% homologous, with the nucleotide sequence shown as SEQ ID NO: 1 in the Sequence Listing.
- nucleotide sequence is degenerate, because of the genetic code, to the nucleotide sequence shown as SEQ ID NO: 1.
- the invention includes a nucleic acid molecule as described above wherein the said human protein kinase B ⁇ , or the functionally equivalent form thereof, comprises at least two regulation phosphorylation sites.
- regulation phosphorylation sites can be assigned to the residues Thr 305 and Ser 472 .
- the nucleic acid molecule according to the invention is coding for human protein kinase B ⁇ , or a functionally equivalent form thereof, which comprises at least 455 amino acids, or more preferably comprises essentially the amino acid sequence shown as positions 455 to 480 in SEQ ID NO: 2.
- this invention provides an isolated human protein kinase B ⁇ polypeptide, encoded by a nucleic acid molecule according to the invention.
- the said human protein kinase B ⁇ polypeptide has an amino acid sequence according to SEQ ID NO: 2 of the Sequence Listing.
- the polypeptide according to the invention is not to be limited strictly to a polypeptide with an amino acid sequence identical with SEQ ID NO: 2 in the Sequence Listing. Rather the invention encompasses polypeptides carrying modifications like substitutions, small deletions, insertions or inversions, which polypeptides nevertheless have substantially the biological activities of protein kinase B ⁇ . Included in the invention are consequently polypeptides, the amino acid sequence of which is at least 85% homologous, preferably at least 90% or 95% homologous, with the amino acid sequence shown as SEQ ID NO: 2 in the Sequence Listing.
- variants, derivatives, and fragments of a protein kinase B ⁇ polypeptide include variants, derivatives, and fragments of a protein kinase B ⁇ polypeptide.
- the skilled person will readily be able to determine whether such a variant, derivative, or fragment of a protein kinase B ⁇ polypeptide displays protein kinase B ⁇ activity by subjecting the variant, derivative, or fragment to a standard protein kinase assay.
- assays are well known in the art, see e.g. Konishi et al. (1995) Biochem. Biophys. Res. Comm. 216, 526-534.
- the present invention also relates to vectors comprising the nucleic acid molecules of the invention, as well as host cells transformed with such vectors. Any of the nucleic acid molecules of the invention may be joined to a vector, which generally includes a selectable marker and an origin of replication, for propagation in a host. Because the invention also provides protein kinase B ⁇ polypeptides expressed from the nucleic acid molecules described above, vectors for the expression of protein kinase B ⁇ are preferred. Such expression vectors include DNA encoding a protein kinase B ⁇ polypeptide, operably linked to suitable transcriptional or translational regulatory sequences, such as those derived from a mammalian, microbial, viral, or insect gene.
- regulatory sequences include transcriptional promoters, operators, or enhancers, mRNA ribosomal binding sites, and appropriate sequences which control transcription and translation.
- Nucleotide sequences are operably linked when the regulatory sequence functionally relates to the DNA encoding protein kinase B ⁇ .
- a promoter nucleotide sequence is operably linked to a PKB DNA sequence if the promoter nucleotide sequence directs the transcription of the PKB sequence.
- the vector may be any vector which may conveniently be subjected to recombinant DNA procedures, and the choice of vector will often depend on the host cell into which it is to be introduced.
- the vector may be an autonomously replicating vector, i.e. a vector which exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication; examples of such a vector are a plasmid, phage, cosmid, mini- chromosome or virus.
- the vector may be one which, when introduced in a host cell, is integrated in the host cell genome and replicated together with the chromosome(s) into which it has been integrated. Examples of suitable vectors are a bacterial expression vector and a yeast expression vector.
- the vector of the invention may carry any of the DNA molecules of the invention as defined above.
- a suitable host cell can be a prokaryotic cell, a unicellular eukaryotic cell or a cell derived from a multicellular organism.
- the host cell can thus e.g. be a bacterial cell such as an E. coli cell; a cell from a yeast such as Saccharomyces cervisiae or Pichia pastoris, or a mammalian cell.
- the methods employed to effect introduction of the vector into the host cell are standard methods well-known to a person familiar with recombinant DNA methods.
- Included in the invention is a process for production of a human protein kinase B ⁇ polypeptide, which comprises culturing a host cell as described above under conditions whereby said polypeptide is produced, and optionally recovering said polypeptide.
- a further aspect of the invention is a nucleic acid probe comprising at least 15 nucleotides, which probe specifically hybridizes with at least a part of the nucleic acid molecule according to the invention, said part having a sequence shown as positions 1363 to 1446 in SEQ ID NO: 1.
- the invention also provides an antisense oligonucleotide having a sequence capable of specifically hybridizing to at least a part of the nucleic acid molecule according to the invention, said part having a sequence shown as positions 1363 to 1446 in SEQ ID NO: 1.
- Fragments of the nucleic acid molecules described herein, as well as polynucleotides capable of hybridizing to such nucleic acid molecules may be used as a probe or as primers in a polymerase chain reaction (PCR).
- PCR polymerase chain reaction
- Such probes may be used, e.g., to detect the presence of nucleic acids coding for PKB in in vitro assays, as well as in Southern and Northern blots. Cell types expressing PKB may also be identified by the use of such probes.
- Such procedures are well known, and the skilled artisan will be able to choose a probe of a length suitable to the particular application.
- 5' and 3' primers corresponding to the termini of a desired PKB nucleic acid molecule are employed to isolate and amplify that sequence using conventional techniques.
- polypeptides of the present invention may also be used to raise polyclonal and monoclonal antibodies, which are useful in diagnostic assays for detecting PKB polypeptide expression.
- Such antibodies may be prepared by conventional techniques. See, for example, Antibodies: A Laboratory Manual, Harlow and Land (eds.), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., (1988); Monoclonal Antibodies, Hybridomas: A New Dimension in Biological Analyses, Kertnet et al. (eds.), Plenum Press, New York (1980).
- Included in the invention is a method for screening for compounds which affect the insulin signaling pathway, comprising
- the invention also provides a method for disrupting the protein kinase B ⁇ gene in a non- human embryonic stem cell, said method comprising (a) providing an oligonucleotide capable of disrupting said protein kinase B ⁇ gene; and (b) introducing said oligonucleotide into the non-human embryonic stem-cell under conditions such that the said oligonucleotide is homologously recombined into at least one of the naturally occurring protein kinase B ⁇ genes in the genome of said cell to produce a cell containing at least one disrupted protein kinase B ⁇ allele.
- the invention further provides a non-human transgenic animal expressing reduced levels of protein kinase B ⁇ , wherein the protein kinase B ⁇ gene has been disrupted by this method.
- the invention also provides a non-human transgenic animal whose genome comprises an antisense nucleic acid molecule which hybridizes to mRNA encoding human protein kinase B ⁇ , thereby reducing its translation.
- a transgenic non-human mammal can e.g. be mammalian animal, such a mouse, or an animal of the species Caenorhabditis elegans.
- the invention also provides a method for screening compounds for affecting the insulin signaling pathway comprising
- Marathon-ReadyTM heart cDNA from Clontech was used as a template for cloning.
- PCR primers shown as SEQ ID NOS: 3 to 6 were used.
- the PCR reactions were performed using Advantage® cDNA polymerase mix from Clontech.
- the 3 '-RACE PCR reaction was performed as described in Marathon-ReadyTM cDNA users manual (PT1156-1) using primers shown as SEQ ID NOS: 3 and 5 and with the following PCR program: +94°C for 5 seconds, +65°C for 30 seconds, +68°C for 3 min, during 30 (+ 5 cycles), with an initial step of +94°C for 30 seconds and a last step of +72°C for 7 min.
- a Perkin Elmer 2400 machine was used.
- the least amplified PCR material was used. This material was purified from agarose gel by using the Wizard PCRpreps DNA purification system and cloned into the plasmid pCR ®2.1-TOPO (Invitrogen) by using the TOPO TA cloning kit (Invitrogen). Plasmid DNA from three clones were obtained by using the QIAprep spin plasmid kit (QIAGEN) and the subsequent sequencing. was performed by the dideoxy chain-termination method using ABI PrismTM 377 DNA sequencer XL (Applied Biosystems) EX AMPLE 2: Northern Blotting
- a probe for northern blot analysis was obtained from the cloned PKB ⁇ by a PCR reaction with primers shown as SEQ ID NOS: 7 and 8 which gave a fragment of 362 bp in the PH domain of the gene.
- the PCR reactions was performed using Advantage® cDNA polymerase mix from Clontech with the following PCR program: +94°C for 30 seconds, +54°C for 30 seconds, +72°C for 1 min for 30 cycles, with an initial step of +94°C for 3 min and a last step of +72°C for 7 min.
- a Perkin Elmer 9700 machine was used.
- the band of interest was excised from agarose gel and purified by using QIAquick Gel Extraction Kit (QIAGEN).
- the probe was radioactively labeled according to the r ⁇ &primeTM II kit (Amersham Pharmacia Biotech). Human Multiple Tissue Northern (MTNTM) Blots (Clontech) was used for hybridization of the cDNA probe as described in the MTN Blots protocol.
- MTNTM Multiple Tissue Northern
- EXAMPLE 3 Use of antisense oligonucleotides for producing knock-out animals
- oligonucleotides from genomic or cDNA's, comprising either the sense or antisense strand of the cDNA sequence can be used in vitro or in vivo to inhibit expression. Such technology is well known in the art, and oligonucleotides or other fragments can be designed from various locations along the sequences.
- the gene of interest can be turned off in the short term by transfecting a cell or tissue with expression vectors which will flood the cell with sense or antisense sequences until all copies of the vector are disabled by endogenous nucleases.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Enzymes And Modification Thereof (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The present invention relates to human protein kinase B η polypeptides and to nucleic acid molecules coding for such polypeptides. The invention further relates to vectors and cells comprising said nucleic acid molecules, as well as to methods for screening test compounds which affect the insulin signaling pathway. In contrast to the previously known protein kinase B η from rat brain, the human protein kinase B η polypeptides comprise two activating phosphorylation residues; Thr305 and Ser472.
Description
HUMAN PROTEIN KINASE B7 POLYPEPTIDES AND A METHOD FOR DISRUPΗNG PROTEIN KINASE B7 IN A NON-HUMAN
TECHNICAL FIELD
The present invention relates to human protein kinase B polypeptides and to nucleic acid molecules coding for such polypeptides. The invention further relates to vectors and cells comprising said nucleic acid molecules, as well as to methods for screening test compounds which affect the insulin signaling pathway.
BACKGROUND ART
Insulin plays a key role in regulating a wide range of cellular processes. The activation of class la phopshoinositide 3-kinase (PI 3-kinase) is necessary to elicit many of insulin's effects on glucose and lipid metabolism (for reviews, see Shepherd, P.R. et al. (1998) Biochem. J. 333, 471-490; Alessi, D.R. & Downes, C.P. (1998) Biochim. Biophys. Acta 1436, 151-164). One of the major ways the lipid products of PI 3-kinase act in insulin signaling is by binding to pleckstrin homology (PH) domains of phosphoinositide- dependent protein kinase (PDK1) and protein kinase b (PKB). This mechanism regulates the activity of serine/threonine-specific kinase cascades important in mediating insulin's effects on endpoint responses.
Protein kinase B (for reviews, see e.g. Coffer, P.J. et al. (1998) Biochem. J. 335, 1-13: Alessi, D.R. & Cohen, P. (1998) Current Opinion in Genetics & Development 8, 55-62) has also been called Akt or RAC (Related to protein kinase A and C). There are three mammalian isoforms of PKB, namely PKBα, PKBβ and PKBγ, but most studies of the regulation and specificity of this enzyme have so far been focused on the PKBα isoform. The activation of PKBα by insulin or insulin growth factor 1 (IGF1) results from its phosphorylation at two residues, Thr308 and Ser 73, which are phosphorylated by distinct enzymes.
In Caenorhabditis elegans it has been shown that two Akt/PKB homologs, called akt-1 and akt-2, transduce insulin receptor-like signals (Paradis, S. & Ruvkun, G. (1998) Genes & Development 12, 2488-2498).
The molecular cloning of human PKB α is disclosed by Jones, P. F. et al. (1991) Proc. Natl. Acad. Sci. U.S.A. 88, 4171-4175. Human PKB β is disclosed by Cheng et al. (1992) Proc. Natl. Acad. Sci. U.S.A. 89, 9267-9271. RAC-protein kinase is disclosed in WO 97/18303.
The article by Konishi, H. et al. (1995) Biochem. Biophys. Res. Comm. 216, 526-534 discloses cloning of PKB γ from a rat brain cDNA library. An isolated cDNA clone had an open reading frame encoding a sequence of 454 amino acids with the molecular weight of 52,845. The amino acid sequence showed approximately 83% and 77% sequence homology with rat PKB α and rat PKB β, respectively.
Like PKB α and PKB β, PKB γ possess an N-terminal PH domain and a residue equivalent to Thr308 (Thr305 in PKB γ). However, on the basis of the disclosure by Konishi et al, it has been generally believed that PKB γ has a C-terminal truncation of 23 residues and thereby lacks a residue equivalent to Ser473 (see e.g. Coffer et al., supra; Alessi & Downes, supra; Alessi & Cohen, supra; Walker et al. (1998) Biochem. J. 331, 299-308). It has thus been believed that PKB γ is activated solely via phosphorylation of Thr305.
DISCLOSURE OF THE INVENTION
It has surprisingly been found that human protein kinase B γ is a protein comprising 479 amino acids, including the 23 amino acid C-terminal region lacking in the enzyme cloned from rat brain (Konishi et al., supra). Human protein kinase B γ comprises not only the phosphorylation residue Thr305 but also a putative second phosphorylation residue Ser472.
In a first aspect this invention provides an isolated nucleic acid molecule selected from:
(a) nucleic acid molecules comprising a nucleotide sequence as shown in SEQ ID NO: 1 and which codes for human protein kinase B γ;
(b) nucleic acid molecules comprising a nucleotide sequence capable of hybridizing under stringent hybridization conditions to a nucleotide sequence complementary the polypeptide coding region of a DNA molecule as defined in (a) and which codes for human protein kinase B γ, or a functionally equivalent modified form thereof; and
(c) nucleic acid molecules comprising a nucleic acid sequence which is degenerate as a result of the genetic code to a nucleotide sequence as defined in (a) or (b) and which codes for human protein kinase B γ, or a functionally equivalent modified form thereof.
The term "stringent hybridization conditions" is known in the art from standard protocols (e.g. Current Protocols in Molecular Biology, editors F. Ausubel et al., John Wiley and Sons, Inc. 1994, or Sambrook, J., Fritsch, E.F. and Maniatis, T., Molecular Cloning: A laboratory manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY 1989) and could be understood as e.g. hybridization to filter-bound DNA in 0.5 M NaHPO4, 7% sodium dodecyl sulfate (SDS), 1 mM EDTA at +65°C, and washing in O.lxSSC / 0.1% SDS at +68°C.
In a preferred form of the invention, the said nucleic acid molecule has a nucleotide sequence identical with SEQ ID NO: 1 of the Sequence Listing. However, the nucleic acid molecule according to the invention is not to be limited strictly to the sequence shown as SEQ ID NO: 1. Rather the invention encompasses nucleic acid molecules carrying modifications like substitutions, small deletions, insertions or inversions, which nevertheless encode proteins having substantially the biochemical activity of protein kinase B γ. Included in the invention are consequently nucleic acid molecules, the nucleotide sequence of which is at least 85% homologous, preferably at least 90 or 95% homologous, with the nucleotide sequence shown as SEQ ID NO: 1 in the Sequence Listing.
Included in the invention is also a DNA molecule which nucleotide sequence is degenerate, because of the genetic code, to the nucleotide sequence shown as SEQ ID NO: 1. A sequential grouping of three nucleotides, a "codon", codes for one amino acid. Since there
are 64 possible codons, but only 20 natural amino acids, most amino acids are coded for by more than one codon. This natural "degeneracy", or "redundancy", of the genetic code is well known in the art. It will thus be appreciated that the DNA sequence shown in the Sequence Listing is only an example within a large but definite group of DNA sequences which will encode the polypeptide as described above.
In a further aspect the invention includes a nucleic acid molecule as described above wherein the said human protein kinase B γ, or the functionally equivalent form thereof, comprises at least two regulation phosphorylation sites. By comparison with the previously known PKB α and PKB β amino acid sequences, regulation phosphorylation sites can be assigned to the residues Thr305 and Ser472.
In a preferred form of the invention, the nucleic acid molecule according to the invention is coding for human protein kinase B γ, or a functionally equivalent form thereof, which comprises at least 455 amino acids, or more preferably comprises essentially the amino acid sequence shown as positions 455 to 480 in SEQ ID NO: 2.
In a further aspect this invention provides an isolated human protein kinase B γ polypeptide, encoded by a nucleic acid molecule according to the invention. In a preferred form, the said human protein kinase B γ polypeptide has an amino acid sequence according to SEQ ID NO: 2 of the Sequence Listing. However, the polypeptide according to the invention is not to be limited strictly to a polypeptide with an amino acid sequence identical with SEQ ID NO: 2 in the Sequence Listing. Rather the invention encompasses polypeptides carrying modifications like substitutions, small deletions, insertions or inversions, which polypeptides nevertheless have substantially the biological activities of protein kinase B γ. Included in the invention are consequently polypeptides, the amino acid sequence of which is at least 85% homologous, preferably at least 90% or 95% homologous, with the amino acid sequence shown as SEQ ID NO: 2 in the Sequence Listing.
Included in the invention are variants, derivatives, and fragments of a protein kinase B γ polypeptide. The skilled person will readily be able to determine whether such a variant,
derivative, or fragment of a protein kinase B γ polypeptide displays protein kinase B γ activity by subjecting the variant, derivative, or fragment to a standard protein kinase assay. Such assays are well known in the art, see e.g. Konishi et al. (1995) Biochem. Biophys. Res. Comm. 216, 526-534.
The present invention also relates to vectors comprising the nucleic acid molecules of the invention, as well as host cells transformed with such vectors. Any of the nucleic acid molecules of the invention may be joined to a vector, which generally includes a selectable marker and an origin of replication, for propagation in a host. Because the invention also provides protein kinase B γ polypeptides expressed from the nucleic acid molecules described above, vectors for the expression of protein kinase B γ are preferred. Such expression vectors include DNA encoding a protein kinase B γ polypeptide, operably linked to suitable transcriptional or translational regulatory sequences, such as those derived from a mammalian, microbial, viral, or insect gene. Examples of regulatory sequences include transcriptional promoters, operators, or enhancers, mRNA ribosomal binding sites, and appropriate sequences which control transcription and translation. Nucleotide sequences are operably linked when the regulatory sequence functionally relates to the DNA encoding protein kinase B γ . Thus, a promoter nucleotide sequence is operably linked to a PKB DNA sequence if the promoter nucleotide sequence directs the transcription of the PKB sequence.
The vector may be any vector which may conveniently be subjected to recombinant DNA procedures, and the choice of vector will often depend on the host cell into which it is to be introduced. Thus, the vector may be an autonomously replicating vector, i.e. a vector which exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication; examples of such a vector are a plasmid, phage, cosmid, mini- chromosome or virus. Alternatively, the vector may be one which, when introduced in a host cell, is integrated in the host cell genome and replicated together with the chromosome(s) into which it has been integrated. Examples of suitable vectors are a bacterial expression vector and a yeast expression vector. The vector of the invention may carry any of the DNA molecules of the invention as defined above.
A suitable host cell can be a prokaryotic cell, a unicellular eukaryotic cell or a cell derived from a multicellular organism. The host cell can thus e.g. be a bacterial cell such as an E. coli cell; a cell from a yeast such as Saccharomyces cervisiae or Pichia pastoris, or a mammalian cell. The methods employed to effect introduction of the vector into the host cell are standard methods well-known to a person familiar with recombinant DNA methods.
Included in the invention is a process for production of a human protein kinase B γ polypeptide, which comprises culturing a host cell as described above under conditions whereby said polypeptide is produced, and optionally recovering said polypeptide.
A further aspect of the invention is a nucleic acid probe comprising at least 15 nucleotides, which probe specifically hybridizes with at least a part of the nucleic acid molecule according to the invention, said part having a sequence shown as positions 1363 to 1446 in SEQ ID NO: 1. The invention also provides an antisense oligonucleotide having a sequence capable of specifically hybridizing to at least a part of the nucleic acid molecule according to the invention, said part having a sequence shown as positions 1363 to 1446 in SEQ ID NO: 1.
Fragments of the nucleic acid molecules described herein, as well as polynucleotides capable of hybridizing to such nucleic acid molecules may be used as a probe or as primers in a polymerase chain reaction (PCR). Such probes may be used, e.g., to detect the presence of nucleic acids coding for PKB in in vitro assays, as well as in Southern and Northern blots. Cell types expressing PKB may also be identified by the use of such probes. Such procedures are well known, and the skilled artisan will be able to choose a probe of a length suitable to the particular application. For PCR, 5' and 3' primers corresponding to the termini of a desired PKB nucleic acid molecule are employed to isolate and amplify that sequence using conventional techniques.
The polypeptides of the present invention may also be used to raise polyclonal and monoclonal antibodies, which are useful in diagnostic assays for detecting PKB polypeptide expression. Such antibodies may be prepared by conventional techniques. See, for example,
Antibodies: A Laboratory Manual, Harlow and Land (eds.), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., (1988); Monoclonal Antibodies, Hybridomas: A New Dimension in Biological Analyses, Kertnet et al. (eds.), Plenum Press, New York (1980).
Included in the invention is a method for screening for compounds which affect the insulin signaling pathway, comprising
(a) providing a human protein kinase B γ polypeptide;
(b) contacting a test compound to the said human protein kinase B γ polypeptide; and
(c) determining the effect of said test compound on said human protein kinase B γ polypeptide.
The invention also provides a method for disrupting the protein kinase B γ gene in a non- human embryonic stem cell, said method comprising (a) providing an oligonucleotide capable of disrupting said protein kinase Bγ gene; and (b) introducing said oligonucleotide into the non-human embryonic stem-cell under conditions such that the said oligonucleotide is homologously recombined into at least one of the naturally occurring protein kinase B γ genes in the genome of said cell to produce a cell containing at least one disrupted protein kinase B γ allele. The invention further provides a non-human transgenic animal expressing reduced levels of protein kinase B γ, wherein the protein kinase B γ gene has been disrupted by this method.
The invention also provides a non-human transgenic animal whose genome comprises an antisense nucleic acid molecule which hybridizes to mRNA encoding human protein kinase B γ, thereby reducing its translation. A transgenic non-human mammal can e.g. be mammalian animal, such a mouse, or an animal of the species Caenorhabditis elegans.
The invention also provides a method for screening compounds for affecting the insulin signaling pathway comprising
(a) providing a non-human animal as described above; (b) providing a composition comprising a test compound in a form suitable for administration to the said non-human animal;
(c) administering said test compound to said non-human animal; and
(d) determining the effect of the test compound on the insulin-signaling pathway.
EXAMPLES
EXAMPLE 1 : Molecular Cloning and Sequence Analysis
Marathon-Ready™ heart cDNA from Clontech was used as a template for cloning. PCR primers shown as SEQ ID NOS: 3 to 6 were used. The PCR reactions were performed using Advantage® cDNA polymerase mix from Clontech. The 3 '-RACE PCR reaction was performed as described in Marathon-Ready™ cDNA users manual (PT1156-1) using primers shown as SEQ ID NOS: 3 and 5 and with the following PCR program: +94°C for 5 seconds, +65°C for 30 seconds, +68°C for 3 min, during 30 (+ 5 cycles), with an initial step of +94°C for 30 seconds and a last step of +72°C for 7 min. A Perkin Elmer 2400 machine was used.
A smear of bands was seen on agarose gel and a second PCR reaction with a nested primer XKOW #43 was performed to see if any of the bands could be amplified further. A band of approximately 2400 bp was distinguished from the others and was excised from agarose gel. After further amplification and purification, the DNA was cleaved with restriction enzymes (Real and Rstl) to verify a similarity with rat PKB γ (Konishi et al., supra).
To clone the PCR fragment in a plasmid vector, the least amplified PCR material was used. This material was purified from agarose gel by using the Wizard PCRpreps DNA purification system and cloned into the plasmid pCR ®2.1-TOPO (Invitrogen) by using the TOPO TA cloning kit (Invitrogen). Plasmid DNA from three clones were obtained by using the QIAprep spin plasmid kit (QIAGEN) and the subsequent sequencing. was performed by the dideoxy chain-termination method using ABI PrismTM 377 DNA sequencer XL (Applied Biosystems)
EX AMPLE 2: Northern Blotting
A probe for northern blot analysis was obtained from the cloned PKB γ by a PCR reaction with primers shown as SEQ ID NOS: 7 and 8 which gave a fragment of 362 bp in the PH domain of the gene. The PCR reactions was performed using Advantage® cDNA polymerase mix from Clontech with the following PCR program: +94°C for 30 seconds, +54°C for 30 seconds, +72°C for 1 min for 30 cycles, with an initial step of +94°C for 3 min and a last step of +72°C for 7 min. A Perkin Elmer 9700 machine was used. The band of interest was excised from agarose gel and purified by using QIAquick Gel Extraction Kit (QIAGEN). The probe was radioactively labeled according to the rø&prime™ II kit (Amersham Pharmacia Biotech). Human Multiple Tissue Northern (MTN™) Blots (Clontech) was used for hybridization of the cDNA probe as described in the MTN Blots protocol.
EXAMPLE 3 : Use of antisense oligonucleotides for producing knock-out animals
Knowledge of the cDNA sequence of protein kinase B γ will enable its use as a tool in sense (Yuossoufian et al. (1993) Mol. Cell. Biol. 13, 98-104) or antisense (Eguchi et al. (1991) Ann. Rev. Biochem 60, 631-652) technologies for the investigation of gene function. Oligonucleotides, from genomic or cDNA's, comprising either the sense or antisense strand of the cDNA sequence can be used in vitro or in vivo to inhibit expression. Such technology is well known in the art, and oligonucleotides or other fragments can be designed from various locations along the sequences. The gene of interest can be turned off in the short term by transfecting a cell or tissue with expression vectors which will flood the cell with sense or antisense sequences until all copies of the vector are disabled by endogenous nucleases.
Claims
1. An isolated nucleic acid molecule selected from:
(a) nucleic acid molecules comprising a nucleotide sequence as shown in SEQ ID NO: 1 and which codes for human protein kinase B γ;
(b) nucleic acid molecules comprising a nucleotide sequence capable of hybridizing under stringent hybridization conditions to a nucleotide sequence complementary the polypeptide coding region of a DNA molecule as defined in (a) and which codes for human protein kinase B γ, or a functionally equivalent modified form thereof; and (c) nucleic acid molecules comprising a nucleic acid sequence which is degenerate as a result of the genetic code to a nucleotide sequence as defined in (a) or (b) and which codes for human protein kinase B γ, or a functionally equivalent modified form thereof.
2. The nucleic acid molecule according to claim 1 which has a sequence homology of above 85% with the nucleic acid molecule having a nucleotide sequence shown as SEQ ID NO: 1.
3. The nucleic acid molecule according to claim 1 or 2 wherein the said human protein kinase B γ, or the functionally equivalent form thereof, comprises at least 455 amino acids.
4. The nucleic acid molecule according to claim 3 wherein the said human protein kinase B γ, or the functionally equivalent form thereof, comprises essentially the amino acid sequence shown as positions 455 to 479 in SEQ ID NO: 2.
5. The nucleic acid molecule according to claim 3 or 4 wherein the said human protein kinase B γ, or the functionally equivalent form thereof, comprises at least two regulation phosphorylation sites.
6. The nucleic acid molecule according to claim 5 wherein the said human protein kinase B γ, or the functionally equivalent form thereof, comprises regulation phosphorylation sites at least at positions 305 and 472 in SEQ ID NO: 2.
7. An isolated human protein kinase B γ polypeptide, encoded by a nucleic acid molecule according to any one of claims 1 to 6.
8. An isolated human protein kinase B γ polypeptide according to claim 7, having essentially an amino acid sequence shown as SEQ ID NO: 2 in the Sequence Listing.
9. A recombinant vector comprising a nucleic acid molecule according to any one of claims 1 to 6.
10. The vector according to claim 9 wherein the said nucleic acid molecule is operably linked to the regulatory elements necessary for the expression of human protein kinase B γ.
11. A cultured host cell harboring a vector according to claim 9 or 10.
12. A process for production of a human protein kinase B γ polypeptide which comprises culturing a host cell according to claim 11 under conditions whereby said polypeptide is produced, and optionally recovering said polypeptide.
13. A nucleic acid probe comprising at least 15 nucleotides, which probe specifically hybridizes with at least a part of the nucleic acid molecule according to claim 4, said part having a sequence shown as positions 1363 to 1446 in SEQ ID NO: 1.
14. An antisense oligonucleotide having a sequence capable of specifically hybridizing to at least a part of the nucleic acid molecule according to claim 4, said part having a sequence shown as positions 1363 to 1446 in SEQ ID NO: 1.
15. An isolated antibody binding specifically to the human protein kinase B γ polypeptide according to claim 7 or 8.
16. A method for screening for compounds which affect the insulin signaling pathway, comprising
(a) providing a human protein kinase B γ polypeptide according to claim 7 or 8;
(b) contacting a test compound to the said human protein kinase B γ polypeptide; and
(c) determining the effect of said test compound on said human protein kinase B γ polypeptide.
17. A method for disrupting the protein kinase B γ gene in a non-human embryonic stem cell, said method comprising
(a) providing an oligonucleotide capable of disrupting said protein kinase B γ gene; and (b) introducing said oligonucleotide into the non-human embryonic stem-cell under conditions such that the said oligonucleotide is homologously recombined into at least one of the naturally occurring protein kinase B γ genes in the genome of said cell to produce a cell containing at least one disrupted protein kinase B γ allele.
18. A non-human transgenic animal expressing reduced levels of protein kinase B γ, wherein the protein kinase B γ gene has been disrupted by the method according to claim 17.
19. A non-human transgenic animal whose genome comprises an antisense nucleic acid molecule which hybridizes to mRNA encoding human protein kinase B γ, thereby reducing its translation.
20. The non-human transgenic animal according to claim 18 or 19 which is a mouse.
21. The non-human transgenic animal according to claim 18 or 19 which is an animal of the species Caenorhabditis elegans.
2. A method for screening compounds for affecting the insulin signaling pathway comprising
(a) providing a non-human transgenic animal according to claim 18 or 19;
(b) providing a composition comprising a test compound in a form suitable for administration to the said non-human animal;
(c) administering said test compound to said non-human animal; and
(d) determining the effect of the test compound on the insulin-signaling pathway.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9901115 | 1999-03-25 | ||
SE9901115A SE9901115D0 (en) | 1999-03-25 | 1999-03-25 | Nucleotide sequences |
PCT/SE2000/000571 WO2000058446A1 (en) | 1999-03-25 | 2000-03-23 | HUMAN PROTEIN KINASE Bη POLYPEPTIDES AND A METHOD FOR DISRUPTING PROTEIN KINASE Bη IN A NON-HUMAN |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1163327A1 true EP1163327A1 (en) | 2001-12-19 |
Family
ID=20415022
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP00921244A Withdrawn EP1163327A1 (en) | 1999-03-25 | 2000-03-23 | Human protein kinase b gamma polypeptides and a method for disrupting protein kinase b gamma in a non-human |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1163327A1 (en) |
JP (1) | JP2002539823A (en) |
AU (1) | AU4158100A (en) |
CA (1) | CA2368379A1 (en) |
SE (1) | SE9901115D0 (en) |
WO (1) | WO2000058446A1 (en) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU3568797A (en) * | 1996-06-07 | 1998-01-05 | Amylin Pharmaceuticals, Inc. | Transgenic mammals lacking expression of amylin |
US5814500A (en) * | 1996-10-31 | 1998-09-29 | The Johns Hopkins University School Of Medicine | Delivery construct for antisense nucleic acids and methods of use |
-
1999
- 1999-03-25 SE SE9901115A patent/SE9901115D0/en unknown
-
2000
- 2000-03-23 AU AU41581/00A patent/AU4158100A/en not_active Abandoned
- 2000-03-23 WO PCT/SE2000/000571 patent/WO2000058446A1/en not_active Application Discontinuation
- 2000-03-23 JP JP2000608727A patent/JP2002539823A/en active Pending
- 2000-03-23 EP EP00921244A patent/EP1163327A1/en not_active Withdrawn
- 2000-03-23 CA CA002368379A patent/CA2368379A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
See references of WO0058446A1 * |
Also Published As
Publication number | Publication date |
---|---|
JP2002539823A (en) | 2002-11-26 |
SE9901115D0 (en) | 1999-03-25 |
CA2368379A1 (en) | 2000-10-05 |
AU4158100A (en) | 2000-10-16 |
WO2000058446A1 (en) | 2000-10-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20050019890A1 (en) | Nitrilase homologs | |
US5591618A (en) | G protein-coupled receptor kinase GRK6 | |
US5932465A (en) | Phosphodiesterase 8A | |
CA2294646A1 (en) | Human catalytic telomerase sub-unit and its diagnostic and therapeutic use | |
TAKESHITA et al. | Amphibian DNases I are characterized by a C-terminal end with a unique, cysteine-rich stretch and by the insertion of a serine residue into the Ca2+-binding site | |
AU2001243521B2 (en) | Novel human g-coupled protein receptor kinases and polynucleotides encoding the same | |
CA2448347C (en) | Novel human hydroxylases and polynucleotides encoding the same | |
EP1163327A1 (en) | Human protein kinase b gamma polypeptides and a method for disrupting protein kinase b gamma in a non-human | |
AU2001257195B2 (en) | Novel human kinase proteins and polynucleotides encoding the same | |
AU783948B2 (en) | Novel human proteases and polynucleotides encoding the same | |
Ruiz-Vázquez et al. | Structure of the Phenylalanine Hydroxylase Gene inDrosophila melanogasterand Evidence of Alternative Promoter Usage | |
AU784540B2 (en) | Novel human kinase protein and polynucleotides encoding the same | |
CA2431007A1 (en) | Novel human kinase and polynucleotides encoding the same | |
US20020147320A1 (en) | Novel human kinase proteins and polynucleotides encoding the same | |
US20020137913A1 (en) | Novel human kinases and polynucleotides encoding the same | |
US20030008365A1 (en) | Novel human kinases and polynucleotides encoding the same | |
US6511840B1 (en) | Human kinase proteins and polynucleotides encoding the same | |
AU783686B2 (en) | Human kinases and polynucleotides encoding the same | |
US20030175949A1 (en) | Novel human kinase and polynucleotides encoding the same | |
CA2443319A1 (en) | Novel human kinase and polynucleotides encoding the same | |
CA2398087A1 (en) | Novel human enzymes and polynucleotides encoding the same | |
AU2005239714A1 (en) | Human kinase proteins and polynucleotides encoding the same | |
CA2425515A1 (en) | Human ion channel protein and polynucleotides encoding the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20011004 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: BIOVITRUM AB |
|
17Q | First examination report despatched |
Effective date: 20030423 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20030904 |